RhumbLine Advisers’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.7M | Buy |
231,600
+73,691
| +47% | +$8.01M | 0.03% | 516 |
|
|
2026
Q1 | $14.6M | Buy |
157,909
+2,091
| +1% | +$210K | 0.01% | 879 |
|
|
2025
Q4 | $15.9M | Sell |
155,818
-24,349
| -14% | -$2.18M | 0.01% | 838 |
|
|
2025
Q3 | $11.3M | Sell |
180,167
-4,557
| -2% | -$248K | 0.01% | 1023 |
|
|
2025
Q2 | $9.61M | Buy |
184,724
+9,292
| +5% | +$415K | 0.01% | 1068 |
|
|
2025
Q1 | $7.47M | Buy |
175,432
+8,202
| +5% | +$354K | 0.01% | 1155 |
|
|
2024
Q4 | $5.11M | Buy |
167,230
+3,529
| +2% | +$99.3K | ﹤0.01% | 1409 |
|
|
2024
Q3 | $3.76M | Sell |
163,701
-9,597
| -6% | -$272K | ﹤0.01% | 1574 |
|
|
2024
Q2 | $5M | Buy |
173,298
+10,162
| +6% | +$237K | ﹤0.01% | 1400 |
|
|
2024
Q1 | $3.37M | Buy |
163,136
+3,890
| +2% | +$83.4K | ﹤0.01% | 1626 |
|
|
2023
Q4 | $4.31M | Sell |
159,246
-414
| -0.3% | -$10.9K | ﹤0.01% | 1509 |
|
|
2023
Q3 | $4.73M | Buy |
159,660
+8,688
| +6% | +$306K | 0.01% | 1384 |
|
|
2023
Q2 | $5.4M | Buy |
150,972
+29,315
| +24% | +$842K | 0.01% | 1329 |
|
|
2023
Q1 | $2.85M | Buy |
121,657
+11,406
| +10% | +$326K | ﹤0.01% | 1627 |
|
|
2022
Q4 | $3M | Buy |
110,251
+4,099
| +4% | +$188K | ﹤0.01% | 1573 |
|
|
2022
Q3 | $5.71M | Buy |
106,152
+8,536
| +9% | +$438K | 0.01% | 1152 |
|
|
2022
Q2 | $3.94M | Buy |
97,616
+15,962
| +20% | +$791K | 0.01% | 1379 |
|
|
2022
Q1 | $5.41M | Sell |
81,654
-4,578
| -5% | -$313K | 0.01% | 1258 |
|
|
2021
Q4 | $8.63M | Buy |
86,232
+2,708
| +3% | +$280K | 0.01% | 1063 |
|
|
2021
Q3 | $10.4M | Sell |
83,524
-708
| -0.8% | -$84.1K | 0.01% | 929 |
|
|
2021
Q2 | $10.5M | Sell |
84,232
-268
| -0.3% | -$36K | 0.01% | 972 |
|
|
2021
Q1 | $12.9M | Sell |
84,500
-2,552
| -3% | -$386K | 0.02% | 838 |
|
|
2020
Q4 | $11.2M | Buy |
87,052
+5,358
| +7% | +$616K | 0.02% | 846 |
|
|
2020
Q3 | $9.13M | Sell |
81,694
-4,645
| -5% | -$425K | 0.01% | 824 |
|
|
2020
Q2 | $7M | Buy |
86,339
+48,550
| +128% | +$3.91M | 0.01% | 984 |
|
|
2020
Q1 | $2.63M | Buy |
37,789
+965
| +3% | +$74.1K | 0.01% | 1395 |
|
|
2019
Q4 | $2.88M | Buy |
36,824
+983
| +3% | +$70.8K | ﹤0.01% | 1587 |
|
|
2019
Q3 | $2.29M | Buy |
35,841
+1,538
| +4% | +$135K | ﹤0.01% | 1669 |
|
|
2019
Q2 | $2.96M | Buy |
34,303
+14,056
| +69% | +$1.07M | 0.01% | 1489 |
|
|
2019
Q1 | $1.55M | Buy |
20,247
+367
| +2% | +$20.3K | ﹤0.01% | 1842 |
|
|
2018
Q4 | $747K | Buy |
+19,880
| New | +$732K | ﹤0.01% | 2131 |
|
Other funds holding GH
DTC
RhumbLine Advisers's GH Position: Q2 2026 in Review
RhumbLine Advisers increased its Guardant Health (GH) stake by 47% in Q2 2026, buying an estimated $8.01M and bringing the position to 231,600 shares worth $34.7M. The position accounts for 0.03% of the portfolio, ranked #516.
RhumbLine Advisers first reported a position in GH in Q4 2018 and has held it in 31 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- RhumbLine Advisers held 231,600 shares of Guardant Health worth $34.7M as of Q2 2026.
- RhumbLine Advisers bought 73,691 Guardant Health shares in Q2 2026, an estimated $8.01M.
- Guardant Health made up 0.03% of RhumbLine Advisers's portfolio in Q2 2026, its #516 holding.
- RhumbLine Advisers first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.